Therefore, in addition to affecting IL-17 production (Figure 1), blocking the IL-12/IFN-γ pathway by TL1A neutralization may also be needed to effectively treat the colonic inflammation associated with human IBD [16]. Here, IL17A is linked to inflammatory bowel disease.